2022 World Conference on Lung Cancer (ePosters)-EP08.02-005. A Prospective Non-randomized Observational Study on Efficacy and Its Relative Factors of Pemetrexed Combined With EGFR-TKIs in NSCLC

EP08.02-005. A Prospective Non-randomized Observational Study on Efficacy and Its Relative Factors of Pemetrexed Combined With EGFR-TKIs in NSCLC

Back to course

Pdf Summary

This study aimed to analyze the efficacy of pemetrexed combined with EGFR-TKIs in the first-line treatment of advanced NSCLC patients. Data from 242 patients with EGFR mutated advanced NSCLC were collected and analyzed. Most patients (215/242) received pemetrexed-platinum chemotherapy combined with EGFR-TKIs, while the remaining 27 patients received mono chemotherapy of pemetrexed combined with EGFR-TKIs. The primary endpoint was the median progression-free survival (mPFS) time, while secondary endpoints included median objective response rate (mORR), disease control rate (DCR), and median overall survival (mOS) time.<br /><br />The results showed that the platinum-based group had a significantly longer mPFS compared to the mono chemotherapy group (15.23 vs 9.90 months). Among the platinum-based group, patients who received maintenance treatment for 2 cycles had significantly prolonged mPFS and mOS compared to those who received maintenance treatment for 2 cycles. The multivariate Cox regression analysis identified brain metastasis as a significant predictive factor for shorter mPFS, while 2 cycles of maintenance treatment were a significant predictive factor for longer mPFS in patients treated with standardized induction therapy group.<br /><br />The baseline characteristics of the enrolled patients were also reported, including age, gender, smoking status, stage, type of genefusion, concomitant mutation (TP53), brain metastasis, and bone metastasis.<br /><br />In conclusion, this study suggests that platinum-based chemotherapy is an important factor in the first-line treatment of advanced NSCLC with pemetrexed combined with EGFR-TKIs. Additionally, maintenance therapy of 2 cycles after four cycles of induction chemotherapy may significantly improve survival.<br /><br />Further research should be conducted to validate these findings and assess the efficacy of this treatment approach in a randomized controlled trial.

Asset Subtitle

Huijuan Wang

Meta Tag

Speaker Huijuan Wang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

pemetrexed combined with EGFR-TKIs

advanced NSCLC patients

efficacy analysis

platinum-based chemotherapy

first-line treatment

progression-free survival

objective response rate

disease control rate

overall survival

maintenance therapy